Clinical Daily Summary
Clinical Daily Summary: What Happened on November 18, 2026
Sellas reports longer survival with AML vaccine in Phase 3
MSD ended its nemtabrutinib trials after a safety review. AriBio’s Alzheimer’s results differed between a prespecified subgroup and the full trial population.
Today in brief
Sellas reported that galinpepimut-S lowered the risk of death in a Phase 3 acute myeloid leukemia trial. Median survival was 24 months, compared with 14.7 months on other treatments.12 MSD ended all three Phase 3 BELLWAVE studies of nemtabrutinib after an external safety committee said the potential benefits might not outweigh the risks.3
AriBio’s AR1001 met its primary endpoint in a prespecified group taking no other Alzheimer’s medicines, but not in the full trial population.4
Sellas reports a survival benefit for its AML vaccine
Sellas said on November 17 that its Phase 3 REGAL trial met its overall-survival goal in people with acute myeloid leukemia who had reached a second or later remission and could not receive a stem-cell transplant.1 Galinpepimut-S cut the risk of death by 41% compared with investigator-selected treatment options, the company reported.1 Median overall survival was 24 months with the vaccine and 14.7 months in the comparison group. The trial randomized 126 participants equally between the groups.12
REGAL was open-label, and the comparison group could receive different treatments or observation. The results therefore do not compare the vaccine with any one specific therapy.1 Sellas is preparing a biologics license application for the first half of 2027 and plans to discuss an accelerated filing approach with the FDA.1
MSD ends nemtabrutinib development after safety review
MSD stopped BELLWAVE-011 and ended the wider Phase 3 BELLWAVE program for nemtabrutinib, including BELLWAVE-008 and BELLWAVE-010.3 An external Data Monitoring Committee advised that the drug’s potential clinical benefits might not outweigh the risks seen in the data.3
MSD reviewed the full dataset and said its safety assessment supported permanently ending the trial and the broader program.3 The company is notifying investigators and recommends that enrolled patients discuss next steps and other treatment options with their doctors.3 MSD said it is still analyzing the studies and plans to share the full results with the scientific community.3
AR1001’s Phase 3 result depended on which patients were counted
AriBio said AR1001 met the primary endpoint in a prespecified group taking the drug alone. The group had a 0.44-point difference on the Clinical Dementia Rating–Sum of Boxes scale, with clinical decline 31% slower.4 In the full study population, the difference on that scale was −0.11 points and was not significant.4
On another Alzheimer’s cognitive test, results numerically favored placebo but were not statistically significant. A separate mental-status measure favored AR1001 by 0.7 points.4 Fatal adverse events occurred in four AR1001 participants and two placebo participants. Adverse events led 5.2% of AR1001 recipients to stop treatment.4 AriBio plans to give the complete trial results to the FDA to guide its next steps.4
Also worth knowing
-
Recursion said its FDA-agreed Phase 3 FAP trial will count removal of an adenoma at least 10 mm across as an event in the primary endpoint. The company plans to start the study in the second half of 2027.5
-
ONL Therapeutics finished enrolling patients in its Phase 2 GALAXY study of xelafaslatide for geographic atrophy, an advanced form of dry age-related macular degeneration.6
-
VedaBio presented proof-of-concept data for a CRISPR-based respiratory diagnostic designed to return results in 10 minutes, the company said.7
-
P
A report from the British Heart Foundation and three partner organizations says people with severe mental illness in England are about four times as likely as the general population to die prematurely from cardiovascular disease.8
Also published
- Priavoid’s oral Alzheimer’s drug falters on Phase II efficacy endpoint Clinical Trials Arena
- From periodic medication review to proactive medication surveillance pharmaphorum
- Sellas stock surges on ‘conversation-changing’ Phase III cancer vaccine victory Clinical Trials Arena
- Measuring Burden Before It Becomes Risk: Coordinator Friction, Tool Fatigue, and Trial Quality Applied Clinical Trials
- STAT+: Flagship opens biotech-creation outpost in the U.K. STAT Biotech
- STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial STAT Biotech
- The Hidden Cost of Clinical Supply: Unlocking Study Cash Flow and Flexibility BioPharm International